Aresa A/S was established in 2001 with the purpose of developing plant technology projects which may help improve the living conditions for human beings and which concurrently offer an attractive commercial potential. The company’s scientific basis derives from the Institute of Molecular Biology and Physiology at the University of Copenhagen.
In connection with the introduction, new shares worth approx. DKK 54 million were sold, and Aresa got some 800 new shareholders.
Jan Ovesen, Deputy President, Copenhagen Stock Exchange says: ”It is a great pleasure to welcome the second company to First North since the market opened in December 2005. We are convinced that the introduction will inspire other small to mid-sized companies to raise capital via the marketplace. The interest that both private and larger-scale investors have shown Aresa confirms our belief that small companies indeed have the attention of the investors”.
CEO Jarne Elleholm from Aresa comments: “Aresa is undergoing rapid development, and with the admission to First North we now have the best framework for establishing the financial basis that is so crucial to achieving the company’s goal of placing unique plant-based products on the market. We are very pleased that so many investors have shown their interesting in Aresa, which means that we can now begin realising our vision.”
